EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐ BCMA CAR T‐cell‐based therapy

Yuekun Qi iD, Hujun Li, Kunming Qi, Feng Zhu, Hai Cheng, Wei Chen iD, Zhiling Yan, Depeng Li, Wei Sang, Xiaoming Fei iD, Weiying Gu, Yuqing Miao und 11 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Yuekun Qi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Blood Diseases Institute Cancer Institute, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Tumor Microenvironment, Immunotherapy, Adoptive, B-Cell Maturation Antigen. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Xuzhou Medical Leading Talents Training Program, Jiangsu Province Key Research & Development Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed/refractory multiple myeloma patients with extramedullary disease (EMD) have unfavorable prognosis and lack effective therapy. Chimeric antigen receptor (CAR) T‐cell activities in EMD have yet to be determined; how EMD‐specific microenvironment influences the clinical outcomes of CAR T‐cell therapy remains of great interest. In this prospective cohort study, patients with histologically confirmed extra‐osseous EMD were enrolled and treated with combined anti‐BCMA and anti‐CD19 CAR T‐cell therapy from May 2017 to September 2023. Thirty‐one patients were included in the study. Overall response occurred in 90.3% of medullary disease and 64.5% of EMD ( p = .031). Discrepancies in treatment response were noted between medullary and extramedullary diseases, with EMD exhibiting suboptimal and delayed response, as well as shortened response duration. With a median follow‐up of 25.3 months, the median progression‐free and overall survival were 5.0 and 9.7 months, respectively. Landmark analysis demonstrated that progression within 6 months post‐infusion is strongly associated with an increased risk of death (HR = 4.58; p = .029). Compared with non‐EMD patients, patients with EMD showed inferior survival outcomes. Unique CAR‐associated local toxicities at EMD were seen in 22.6% patients and correlated with the occurrence and severity of systemic cytokine release syndrome. To the cutoff date, 65% treated patients experienced EMD progression, primarily in the form of BCMA + progression. The pretherapy EMD immunosuppressive microenvironment, characterized by infiltration of exhausted CD8 + T cells, was associated with inferior clinical outcomes. CAR T cells have therapeutic activity in relapsed/refractory EMD, but the long‐term survival benefits may be limited. EMD‐specific microenvironment potentially impacts treatment. Further efforts are needed to extend EMD remission and improve long‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTumor MicroenvironmentImmunotherapy, AdoptiveB-Cell Maturation AntigenHumansMaleMiddle AgedFemaleAgedProspective StudiesAdultReceptors, Chimeric AntigenTreatment Outcome

Substanzen

B-Cell Maturation AntigenReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Blood Diseases Institute Cancer Institute, Xuzhou Medical University, Xuzhou, China.
  • Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, China.
  • Department of Hematology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Department of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, China.
  • Department of Hematology, The First People's Hospital of Yancheng, Yancheng, China.

ORCID-Profile: Yuekun Qi, Wei Chen, Xiaoming Fei, Ying Wang, Bin Pan, Zhenyu Li, Kailin Xu, Jiang Cao

Förderung

  • National Natural Science Foundation of China
  • Xuzhou Medical Leading Talents Training Program
  • Jiangsu Province Key Research & Development Plan

Zitieren

APA

Qi, Y., Li, H., Qi, K., Zhu, F., Cheng, H., Chen, W., Yan, Z., Li, D., Sang, W., Fei, X., Gu, W., Miao, Y., Huang, H., Wang, Y., Qiu, T., Qiao, J., Pan, B., Shi, M., Wang, G., …, & Cao, J. (2024). Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐ BCMA CAR T‐cell‐based therapy. American Journal of Hematology. https://doi.org/10.1002/ajh.27469

Vancouver

Qi Y, Li H, Qi K, Zhu F, Cheng H, Chen W, et al. Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐ BCMA CAR T‐cell‐based therapy. American Journal of Hematology. 2024. doi:10.1002/ajh.27469

BibTeX
@article{Qi2024,
  author = {Qi, Yuekun and Li, Hujun and Qi, Kunming and Zhu, Feng and Cheng, Hai and Chen, Wei and Yan, Zhiling and Li, Depeng and Sang, Wei and Fei, Xiaoming and Gu, Weiying and Miao, Yuqing and Huang, Hongming and Wang, Ying and Qiu, Tingting and Qiao, Jianlin and Pan, Bin and Shi, Ming and Wang, Gang and Li, Zhenyu and Zheng, Junnian and Xu, Kailin and Cao, Jiang},
  title = {Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐ BCMA CAR T‐cell‐based therapy},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27469}
}
Kostenlos starten →